HOME BRAIN CANCER AUTOLITT® PHYSICIANS COMPANY CONTACT
  Expand / Contract
-Brain Cancer
Incidence Primary Tumors Metastatic Tumors Brain Tumor Treatment Reference
-AutoLITT®
News AutoLITT® Interstitial Thermal Therapy AutoLITT System Treatment Animation Pre-Clinical Studies Clinical Studies and Trials Milestones
-Physicians
Physicians
-Company
Overview Mission Management Advisors Careers
-Contact
Contact Directions US Directions Canada
 
CLINICAL STUDIES AND TRIALS

 previous page / next page
A Prospective First-in-Man (FIM) Safety Study of the AutoLITT® Laser Treatment of Recurrent/Progressive Brain Tumors
• Monteris Medical, Inc. has completed the patient enrollment for a Phase I study to evaluate the safety and feasibility of the AutoLITT® System* in the treatment of recurrent or progressive Grade IV Glioblastoma Multiforme (GBM) brain tumors.
• The study was completed at the following institutions:

Cleveland Clinic

Gene Barnett, M.D., F.A.C.S
Principal Investigator
Director, Brain Tumor & Neuro-Oncology Ctr
 
Cleveland Clinic - R20
9500 Euclid Avenue
Cleveland, Ohio 44195
 

University Hospitals Case Medical Center

Andrew E. Sloan, M.D., F.A.C.S.
Principal Investigator
Director, Brain Tumor & Neuro-Oncology Ctr
 
University Hospitals Case Medical Center
11100 Euclid Avenue, Han 524
Cleveland, Ohio 44106

 
Future Studies
Monteris will soon announce details of several future clinical studies.
 
 
* The AutoLITT® System has clearance from the Food and Drug Administration (FDA) for use only in the United States. Contact Brad Fercho 269-567-8727 or e-mail bfercho@monteris.com for more information.
® Registered trademark of Monteris Medical, Inc.

previous page / next page

secure login
© Copyright Monteris Medical All rights reserved.